Most glucagon-like peptide-1 side effects are common enough to plan for, not vague enough to hand-wave.
The useful distinction is expected versus unsafe. Nausea after a dose increase is common. Severe persistent abdominal pain, repeated vomiting, dehydration, allergy symptoms, gallbladder signs, low-glucose symptoms, or confusing compounded-product instructions belong in a different lane.
That distinction matters for women after 40 because side effects can collide with protein intake, resistance training, reflux, constipation, gallbladder history, kidney vulnerability, diabetes medicines, menopause sleep disruption, and the long-term maintenance plan.
The common side effects are mostly gastrointestinal
Glucagon-like peptide-1 medicines slow gastric emptying and change appetite signaling. The side-effect pattern follows that mechanism.
| Side effect | Semaglutide 2.4 mg / Wegovy label | Tirzepatide / Zepbound label | What to plan before starting |
|---|---|---|---|
| Nausea | 44% versus 16% placebo in adult weight-management trials. [1] | 25-29% depending on dose versus 8% placebo. [2] | Smaller meals, slower eating, hydration, and a plan if protein intake drops. |
| Diarrhea | 30% versus 16% placebo. [1] | 19-23% depending on dose versus 8% placebo. [2] | Fluid and electrolyte plan, especially with kidney risk or blood-pressure medicines. |
| Vomiting | 24% versus 6% placebo. [1] | 8-13% depending on dose versus 2% placebo. [2] | When to hold the next dose, call the prescriber, or seek urgent care. |
| Constipation | 24% versus 11% placebo. [1] | 11-17% depending on dose versus 5% placebo. [2] | Bowel routine before escalation, not after constipation becomes severe. |
| Abdominal pain or reflux | Abdominal pain and reflux are label-listed adverse reactions. [1] | Abdominal pain, dyspepsia, belching, and heartburn are label-listed. [2] | Distinguish tolerability from gallbladder, pancreatitis, or obstruction concern. |
Pooled STEP 1-3 semaglutide 2.4 mg data show the same shape: nausea affected 43.9% versus 16.1% with placebo, diarrhea 29.7% versus 15.9%, vomiting 24.5% versus 6.3%, and constipation 24.2% versus 11.1%. Most gastrointestinal events were non-serious, mild-to-moderate, and transient, but 4.3% of semaglutide-treated participants permanently discontinued because of gastrointestinal adverse events. [3]
The point is not to scare someone away from treatment. It is to make side effects observable early enough to adjust the plan.
Dose escalation is where tolerability gets tested
Many side effects appear or worsen when the dose changes.
In SURMOUNT-1, the 72-week tirzepatide obesity trial, the most common adverse events were gastrointestinal, usually mild-to-moderate, and occurred primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, and 6.2% of participants receiving tirzepatide 5 mg, 10 mg, and 15 mg, compared with 2.6% on placebo. [4]
That is why a good care plan names what happens before the dose goes up:
| Escalation question | Why it matters |
|---|---|
| Is nausea improving between doses? | Persistent nausea can make protein, fluids, and medicines harder to keep down. |
| Is constipation already difficult? | A dose increase can turn a nuisance into a treatment-limiting problem. |
| Is reflux worse? | Reflux can affect sleep, meals, medication timing, and chest-symptom interpretation. |
| Is hydration stable? | Vomiting or diarrhea can create kidney risk, especially in vulnerable patients. |
| Is appetite too low to support strength training? | Weight loss without enough protein and resistance work can worsen lean-mass loss risk. |
Women after menopause often need the side-effect plan tied to muscle, bone, hydration, blood pressure, glucose risk, sleep, and medication review, not only the scale.
Red flags need a stop-and-call plan
Labels separate common side effects from warnings and precautions.
| Red flag | Why it changes the response |
|---|---|
| Severe persistent abdominal pain, especially with vomiting or back-radiating pain | Wegovy and Zepbound labels warn about acute pancreatitis and instruct discontinuation if pancreatitis is suspected. [1] [2] |
| Right-upper-abdominal pain, jaundice, fever, or clay-colored stools | Glucagon-like peptide-1 receptor agonist use has been associated with increased gallbladder or biliary disease risk in a 76-trial meta-analysis. [5] |
| Repeated vomiting, diarrhea that does not stop, reduced urination, dizziness, or fainting | Labels warn about kidney injury from volume depletion after gastrointestinal symptoms. [1] [2] |
| Swelling of the face, lips, tongue, or throat, trouble breathing, or widespread hives | Labels warn about serious hypersensitivity reactions. [1] [2] |
| Sweating, shaking, confusion, hunger, palpitations, or measured low glucose while using insulin or a sulfonylurea | Labels warn that diabetes medicines that raise insulin can increase hypoglycemia risk when used with these drugs. [1] [2] |
| Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 | Wegovy and Zepbound are contraindicated in these patients. [1] [2] |
| Known or suspected pregnancy | Weight loss offers no benefit in pregnancy and may cause fetal harm; pregnancy planning needs prescriber review. [1] [2] |
Expected nausea can be managed. Red flags need a clinician response.
Compounded GLP-1s add a source-and-dose layer
Compounding is not automatically bad. It can be clinically useful when a licensed clinician has a patient-specific reason an FDA-approved product cannot meet the need, such as an allergy to an inactive ingredient, a dosage-form problem, or a situation where a drug is not commercially available and legal conditions are met. FDA says compounding can serve an important patient need in those situations. [7]
That flexibility is one of the benefits of a responsible compounded pathway. Dosing can be individualized, and a prescriber can make formulation decisions for a particular patient rather than forcing every patient into the same commercial presentation.
The safety boundary is that compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before marketing. [7]
For glucagon-like peptide-1 treatment specifically, FDA's June 15, 2026 page says unapproved versions can be risky because they do not undergo FDA review before marketing. It also lists concerns with compounded semaglutide and tirzepatide: dosing errors, doses beyond labeled schedules, salt forms of semaglutide, shipping or storage problems, fraudulent products, and underreported adverse events. [6]
That makes the practical questions different:
| Compounded-treatment question | Why it matters |
|---|---|
| What patient-specific reason is being solved? | Personalization should solve a real clinical or access problem, not hide a generic copy. |
| What exact active ingredient and salt form are being used? | FDA says semaglutide sodium and semaglutide acetate are different active ingredients from approved semaglutide products. [6] |
| What concentration and syringe instructions are used? | FDA has received reports of overdoses related to measuring or prescribing errors. [6] |
| Who compounds and dispenses it? | FDA recommends prescriptions be filled at a state-licensed pharmacy and warns about online red flags. [6] |
| What happens if side effects appear? | A compounded plan needs the same red-flag, hydration, dose-hold, and adverse-event reporting pathway as any other prescription. |
The balanced view is simple: compounding can support personalization when there is a legitimate patient-specific need, but it should raise the documentation standard, not lower it.
Who this fits
This page fits women comparing glucagon-like peptide-1 options, starting treatment, increasing a dose, switching products, or deciding whether a side effect is expected or unsafe.
It also fits patients considering a compounded version who need a neutral checklist: what flexibility could help, what risk controls should exist, and what would make the source or dosing too unclear.
The evidence is limited when side effects are treated as a single yes-or-no issue. The better question is: which product, dose, source, escalation schedule, medical history, and symptom pattern are we talking about?
What to ask a clinician
Ask:
- Which product and dose are we using, and what side effects are most likely during the first 8 to 12 weeks?
- Which symptoms mean I should hold the next dose, call you, or seek urgent care?
- Should escalation slow down if nausea, vomiting, reflux, diarrhea, or constipation persists?
- How should I protect hydration, protein, resistance training, and bowel function while appetite is lower?
- Do my gallbladder history, pancreatitis history, kidney function, reflux, constipation, diabetes medicines, thyroid medicines, or other prescriptions change the plan?
- If this is compounded, what patient-specific need is it solving, what pharmacy is making it, what concentration is used, and how exactly do I measure the dose?
- If side effects force a pause, what is the maintenance plan?
Bottom line
Glucagon-like peptide-1 side effects are common enough to plan for. Nausea, diarrhea, vomiting, constipation, abdominal pain, reflux, and appetite change often cluster around starting or increasing the dose.
Red flags are different: severe persistent abdominal pain, repeated vomiting, dehydration, gallbladder signs, allergic symptoms, low-glucose symptoms, pregnancy possibility, contraindication history, or unclear compounded-product instructions need clinician review. The safest plan treats side effects as part of prescribing, not as an afterthought.
Related reading:
- Glucagon-like peptide-1 side effects after menopause.
- Compounded Semaglutide After Menopause.
- Glucagon-like peptide-1 dose escalation after menopause.
- Glucagon-like peptide-1 kidney risk after menopause.
References
[1] DailyMed. WEGOVY semaglutide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed. ZEPBOUND tirzepatide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551 https://pubmed.ncbi.nlm.nih.gov/34514682/
[4] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/nejmoa2206038 https://pubmed.ncbi.nlm.nih.gov/35658024/
[5] He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-519. doi:10.1001/jamainternmed.2022.0338 https://pubmed.ncbi.nlm.nih.gov/35344001/
[6] FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[7] FDA. Compounding and the FDA: Questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers